Dosage compensation in *Drosophila*---a fascinating story {#Sec1}
=========================================================

Different numbers or types of sex chromosomes bring about the distinction between heterogametic and homogametic individuals. Unequal distribution of chromosomes normally results in dramatic changes in gene dosage that can lead to developmental defects or death. Therefore, in parallel with sex chromosomes, animals have evolved mechanisms that ensure equalization of gene expression levels between males and females. These processes evolved independently several times during evolution, and they are collectively termed dosage compensation. The mechanisms of dosage compensation vary largely between different organisms and involve different molecular factors. However, the common theme among all model systems of dosage compensation, which have been analyzed at the molecular level, is their regulation at the level of chromatin.

One of the prominent dosage compensation model systems, which has been genetically and biochemically studied, is the hyperactive X chromosome in male fruit flies. Moreover, dosage compensation as a general principle was first described in *Drosophila melanogaster* (Bridges [@CR13]). In contrast to mammals (for a review, see Heard and Disteche [@CR44]), in *Drosophila* females (XX), both X chromosomes are actively transcribed. Accordingly, *Drosophila* males (XY) have to increase their transcription from the single X chromosome about twofold to compensate for the different gene dosage (see Fig. [1](#Fig1){ref-type="fig"}). Molecular factors that have male-specific lethal (MSL) phenotype have been genetically identified (for reviews, see Akhtar [@CR1]; Gilfillan et al. [@CR36]; and Lucchesi et al. [@CR63]). Most of the factors required for dosage compensation in *Drosophila* have been found in a series of genetic screens for mutants that exhibit *male-specific lethality* (Belote and Lucchesi [@CR9]; Fukunaga et al. [@CR33]; Hilfiker et al. [@CR46]). Fig. 1Dosage compensation in *Drosophila*. Dosage compensation in *Drosophila* involves an approximately twofold transcriptional upregulation of the single male X chromosome in comparison to female X chromosomes (**a**). This is mediated by an RNA/protein MSL complex or dosage compensation complex (DCC) which is composed of at least five proteins: MSL1, MSL2, MSL3, MOF, and MLE, and two noncoding RNAs roX1 and roX2 (**b**). The MSL complex is responsible for hyperacetylation of histone H4 lysine 16 (H4K16) on the male X chromosome

The proteins encoded by the male specific lethal genes are collectively named MSLs and include MSL1, MSL2, MSL3, MLE (*maleless*), and MOF (***m****ales absent****o****n the****f****irst*). Immunofluorescence studies beautifully visualized these proteins colocalizing on hundreds of sites along the male X chromosome, suggesting that they might work together at specific chromosomal sites to promote dosage compensation (see Fig. [2](#Fig2){ref-type="fig"}) (Kuroda et al. [@CR57]; Palmer et al. [@CR79]). Indeed, biochemical characterization of MSLs confirmed that they interact physically and form an X-chromosome-specific MSL complex or the dosage compensation complex (DCC) (Copps et al. [@CR23]; Meller et al. [@CR67]; Mendjan et al. [@CR68]; Scott et al. [@CR87]; Smith et al. [@CR90]). Moreover, two noncoding RNAs, roX1 and roX2 (RNA on the X), colocalize specifically with MSLs on the X (Amrein and Axel [@CR6]; Meller et al. [@CR66]). The roX1/roX2 double-mutant flies exhibit an MSL phenotype, and both RNAs were shown to interact with the MSL complex (Franke and Baker [@CR32]; Meller and Rattner [@CR65]; Meller et al. [@CR66]; Smith et al. [@CR90]). MSLs and roX RNAs assemble together at specific nucleation sites on the X chromosome, which have various affinities for the MSL complex (Dahlsveen et al. [@CR26]; Demakova et al. [@CR27]; Kelley et al. [@CR54]). Fig. 2MSL proteins are enriched on the male X chromosome. Polytene chromosomes from the male third instar larvae were immunostained with antibodies against MSL3 (*green*) and MSL2 (*orange*). DNA is visualized by Hoechst (*blue*). The figure illustrates that MSL proteins specifically recognize and colocalize on hundreds of sites on the male X chromosome

Thus, the MSL complex is a unique ribonucleoprotein complex that specifically recognizes the male X chromosome and mediates a twofold transcriptional upregulation of most X-linked genes irrespective of their inherent differences in expression levels.

Lessons from MSLs---together they are strong {#Sec2}
============================================

One of the key questions is how does the MSL complex achieve a twofold increase in transcription on the male X chromosome? One way to get some hints about what activities and molecular mechanisms might be associated with the MSL complex is to analyze its components. MSL proteins contain several domains that are generally implicated in chromatin regulation. MSL1 is a PEHE domain containing protein, MSL2 contains a RING finger and a cysteine-rich cluster, and MSL3 contains a chromo-barrel domain and an MRG domain. MLE and MOF contain enzymatic activities that are associated with the MSL complex. MLE is an RNA/DNA helicase also containing a double-stranded RNA binding domain, and MOF is a histone H4 lysine 16 (H4K16) specific histone acetyltransferase (HAT), which in addition to the HAT domain also contains a chromo-barrel domain and a zinc finger (Fig. [3](#Fig3){ref-type="fig"}, Table [1](#Tab1){ref-type="table"}, and references therein). Over the years, several studies using in vitro and in vivo approaches have provided a wealth of information about important interaction regions in MSL proteins as well as roX RNAs. A brief summary of the mapping studies is provided in Table [1](#Tab1){ref-type="table"} (also see Gilfillan et al. [@CR36]; Rea and Akhtar [@CR83]; and Taipale and Akhtar [@CR100] for reviews). However, despite several in-depth studies, analysis of MSL proteins continues to provide us with new and interesting insights about the complex properties of MSL proteins. Some of the recent advances are discussed below. Fig. 3Domains in MSL complex members. Schematic representation of domain organization in MSL complex members (not drawn to scale)Table 1Summary of deletion mapping and interaction studies of MSL proteins and roX RNAsMSL complex members (domains/motifs)Functions and interactionsReferencesMSL-1 (1039aa): basic motif, acidic region, coiled coil, PEHE motifProtein region 85--186-aa required for interaction with MSL-2 RING fingerCopps et al. [@CR23]N terminus of MSL-1 required for X-chromosome binding and MSL-1 self-associationLi et al. [@CR61]C terminus interacts with MOF in vivo.Scott et al. [@CR87]A 84-aa N-terminal deletion that still interacts with MSL-2, fails to localize to the X, and causes male lethality.Scott et al. [@CR87]MSL-1 is unstable in MSL-2 mutants, and it is stabilized in MSL-2 overexpressing females.Chang and Kuroda [@CR20]PEHE motif essential for binding to MOF in vitroMorales et al. [@CR70]MSL-2 (773aa): RING finger, coiled coilMSL-2 RING finger required for interaction with MSL-2 and male viabilityCopps et al. [@CR23]Various critical RING finger point mutants fail to rescue *msl-2* flies.Lyman et al. [@CR64]Sex lethal binds 3′ and 5′ MSL-2 mRNA and inhibits MSL-2 translation in females.Bashaw and Baker [@CR8]; Kelley et al. [@CR53]; Gebauer et al. [@CR35]Ectopic MSL-2 expression causes lethality in females that is dependent on MSL-1 levels.Kelley et al. [@CR52]MSL-3 (512aa): chromo-barrel domain, MRG domainChromo-barrel domain binds RNA in vitro.Akhtar et al. [@CR4]Chromo-barrel domain is required for dosage compensation but for targeting of the DCC.Buscaino et al. [@CR15]; Morales et al. [@CR71]MSL-3 associates with roX2 RNA in Schneider cells.Buscaino et al. [@CR14]MSL-3 is acetylated by MOF in vitro and in vivo.Buscaino et al. [@CR14]DCC binds only to high-affinity sites in MSL-3 mutants.Lyman et al. [@CR64]MRG domain is required for DCC targeting and assembly.Buscaino et al. [@CR15]; Morales et al. [@CR71]MSL-3 interacts directly with MOF and stimulates its HAT activity.Morales et al. [@CR70]MOF (827aa): chromo-barrel domain, zinc finger, HAT domainHAT domain point mutant causes male-specific lethality.Hilfiker et al. [@CR46]HAT domain required for specific acetylation of H4k16AcSmith et al. [@CR90]; Akhtar and Becker [@CR3]Only enzymatically active MOF activates transcription in vitro.Akhtar and Becker [@CR2]Chromo-barrel domain binds RNA in vitro.Akhtar et al. [@CR4]; Nielsen et al. [@CR75]C2HC zinc finger required for nucleosome binding in vitroAkhtar and Becker [@CR3]MOF associates with roX2 in vivo in Schneider cells.Akhtar et al. [@CR4]; Mendjan et al. [@CR68]MLE (1293aa): dsRNA-binding domain, helicase domainHelicase activity on RNA: RNA, RNA: DNA, and DNA: DNA hybridsLee et al. [@CR58]ATPase activity and DExD box important for male viabilityRichter et al. [@CR85]ATPase activity required for complex spreading along the XLee et al. [@CR58]; Gu et al. [@CR41]Helicase activity essential for roX RNA stabilityGu et al. [@CR41]roX2 associates with MLE in vivo.Meller et al. [@CR67]The C terminus (941--1293-aa) can associate with chromatin in an RNAse-sensitive manner.Richter et al. [@CR85]No action potential (*nap*) allele of MLE required for mRNA processing of *para*Reenan et al. [@CR84]roX1/roX2 (3.7 kb/0.6 kb): roX1 stem loopIn roX1/roX2 double mutants, the DCC is not properly targeted to the X.Meller and Rattner [@CR65]MSL-1 and MSL-2 overexpression partially rescues male lethality in roX mutants.Oh et al. [@CR76]Stem loop in roX1 important for roX1 functionStuckenholz et al. [@CR97]roX2 variable splicing influences DCC assembly on the X chromosome.Park et al. [@CR81]Approximately 10% deletions of roX1 do not affect roX functionStuckenholz et al. [@CR97]

One of the best-characterized proteins of the MSL complex is the HAT MOF that specifically acetylates lysine 16 on histone H4 (H4K16Ac) on the X chromosome (Hilfiker et al. [@CR46]). The HAT activity of MOF has been suggested to directly contribute to the stimulation of transcription and therefore has a direct impact on dosage compensation (Akhtar and Becker [@CR2]; Hilfiker et al. [@CR46]). MOF requires to be incorporated into the MSL complex via interactions with MSL3 and MSL1 to exhibit its full enzymatic activity (Morales et al. [@CR70]). As mentioned above besides the HAT domain, MOF contains a chromo-barrel domain similar to MSL3. Chromo-barrel domains have similarity to chromodomains, which have been shown to bind methylated histones, DNA, and RNA (Bernstein et al. [@CR10]; Bouazoune et al. [@CR12]; Flanagan et al. [@CR31]; Min et al. [@CR69]). Chromodomains comprise an essential part of the histone code hypothesis that explains transcriptional regulation through binding and recruitment of specific regulators dependent on specific combinations of histone modifications (Strahl and Allis [@CR95]). Therefore, the question arises if these domains contribute to something like an X chromosomal histone code. The structure of the MOF chromo-barrel domain has revealed that this domain (also present in MSL3) is structurally distinct from the canonical chromodomains found in numerous chromatin-related proteins (Nielsen et al. [@CR75]). MOF chromo-barrel domain is composed of β-barrels, while the canonical chromodomains have an α + β fold. It is interesting to note that this structure resembles the HP1 chromodomain bound to methylated histone H3 lysine 9 (H3K9) (Nielsen et al. [@CR74]), suggesting that the MOF chromo-barrel domain would not be able to accommodate a methylated histone tail. This poses an interesting question as to the function of MOF chromo-barrel domain. The MOF chromo-barrel domain and its adjacent lysine-rich region are required for RNA binding in vitro (Akhtar et al. [@CR4]; Nielsen et al. [@CR75]). It remains to be seen how this region of MOF mechanistically participates in RNA interaction and whether the chromo-barrel domain may also be able to recognize some other histone modifications.

In contrast to MOF, the chromo-barrel domain of MSL3 might be involved in the binding of methylated residues as the aromatic residues required for coordination of methylated lysines are conserved in MSL3. However, mutations in two of the conserved hydrophobic residues in MSL3 chromo-barrel domain do not lead to any visible functional consequences in flies, suggesting that there is no binding in vivo or that additional residues might contribute to the interaction (Buscaino et al. [@CR15]). What residue could be recognized by MSL3 is still a matter of speculation. Histone H3 lysine 36 (H3K36) is a likely candidate because the chromodomain of EAF3, the yeast homologue of MSL3, has recently been shown to bind this modification (Carrozza et al. [@CR17]; Joshi and Struhl [@CR51]; Keogh et al. [@CR55]). However, experimental evidence for such an interaction by MSL3 chromo-barrel domain is still lacking. It would indeed be an interesting possibility if another histone modification in addition to H4K16Ac would contribute to the X-chromosomal epigenetic code.

Deletion analysis of different domains that contribute to the function of MSL3 brought some unexpected insights about the complexity of dosage compensation (Buscaino et al. [@CR15]; Morales et al. [@CR71]). MSL3 contains an MRG domain (*MORF4-related gene* family) that is found throughout eukaryotes from yeast to humans, with an unknown function (Bertram and Pereira-Smith [@CR11]). This domain is required for proper targeting and integration of MSL3 into the MSL complex on the X chromosome (Morales et al. [@CR71]). However, this is not sufficient to achieve dosage compensation because the chromo-barrel domain is essential for dosage compensation (Buscaino et al. [@CR15]). Hence, the process of dosage compensation contains at least two functionally distinct stages---firstly, recruitment and targeting of the MSL complex to the X chromosome, and secondly, stimulation of X-linked gene expression (Buscaino et al. [@CR15]).

The multifunctionality of MSL3 illustrates some of the complexities that are involved in the mechanism of dosage compensation. While MOF and MSL3 contain domains clearly involved in chromatin regulation, the role of MSL1 and MSL2 in chromatin regulation is more enigmatic. These proteins interact directly through conserved motifs in the N terminus of MSL1 (Copps et al. [@CR23]). Moreover, the N terminus is also required for the binding of MSL1 to the male X chromosome in vivo and for MSL1 self-association in vitro (Li et al. [@CR61]). Potential MSL1 self-association introduces a perspective that favors a structure-mediated function of the MSL complex. This view is further supported by live cell photo-bleaching experiments with GFP-MSL2, which suggest an extraordinary stable association of MSL2 with the X chromosome (Straub et al. [@CR96]). Consequently, the MSL complex might not be a classical chromatin remodeling complex because at least some of its components do not exhibit the high mobility typical for other chromatin remodeling complexes. It remains possible that stable and specific association of MSLs on X-chromosomal genes induces a specific chromosomal configuration, which is particularly permissive to increased and/or regulated transcription.

In summary, the characterization of various domains in MSL proteins suggests a role of the MSL complex at more than one level of chromatin regulation. However, the existence of an X-chromosomal epigenetic code remains a pure speculation because the specific interactions between chromatin modules and corresponding histone modification have not been found yet.

Walking on the X---tracking the footsteps of MSLs {#Sec3}
=================================================

For many years, one of the major questions about dosage compensation in *Drosophila* has been how MSLs specifically recognize the X and what are the binding sites of the MSL complex on the X chromosome. This is of general interest because there is no simple X-chromosomally specific DNA sequence that could explain the preference of MSLs for the X instead of autosomes. Polytene chromosome spreads have provided a formidable system for visualization of MSL binding on the male X chromosome (Fig. [2](#Fig2){ref-type="fig"}). Hundreds of distinct bands bound by the MSL complex can be reproducibly immunostained by specific antibodies against MSL proteins or roX1/2 RNA fluorescence in situ hybridization (Kuroda et al. [@CR57]; Meller et al. [@CR66]). Two of these sites are roX1 and roX2 genomic loci that are bound strongly by the MSL complex. Initially, it was proposed that these are sites of MSL complex assembly, which then further spreads *in cis* over other binding sites on the X chromosome (Kelley et al. [@CR54]). The characterization of translocations of X fragments to autosomes has led to an alternative model proposing sites on the X chromosome with different affinities for the MSL complex (Fagegaltier and Baker [@CR29]; Oh et al. [@CR77]). The affinity model suggests that there is an X-specific hierarchy of binding affinities for MSL proteins. In addition, there is also a clear hierarchy in complex assembly on the X chromosome that distinguishes MSL1 and MSL2 as essential for further binding of other complex components (Lucchesi et al. [@CR63]). Consequently, specific MSL recruitment to the X chromosome seems to be a complex interplay between different *cis*- and *trans*-acting factors. MSL proteins appear to have intrinsic affinity for X-chromosomal sequences, which is tightly balanced with their expression levels and interaction with roX RNAs, as demonstrated by the observations that overexpression of MSL1 and MSL2 complex can partially rescue male lethality in the absence of roX RNAs (Oh et al. [@CR76]; Park et al. [@CR80]).

The identification of MSL binding sites in more detail required sophisticated mapping approaches because polytene chromosomes, although very useful, provide limited resolution at the molecular level. The development of functional genomic approaches like chromatin immunoprecipitation coupled with DNA microarrays (ChIP-chip) finally allowed the assessment of this question on a global scale. Previous ChIP experiments suggested that the complex binds some dosage-compensated genes in the 3′ coding region, but the question remained whether this also had a global significance (Smith et al. [@CR91]). Three recent studies reported the binding pattern of MSL proteins on the X chromosome using various experimental platforms (Alekseyenko et al. [@CR5]; Gilfillan et al. [@CR37]; Legube et al. [@CR59]). These studies, consistent with earlier observations, revealed the preference of the MSL complex to bind to gene coding regions and in particular to the 3′ end of genes (Alekseyenko et al. [@CR5]; Gilfillan et al. [@CR37]). It is interesting to note that studies comparing the binding profiles of MSL1 in embryos and larvae showed that the binding pattern of MSL1 does not dramatically change at different stages of development (Kotlikova et al. [@CR56]; Legube et al. [@CR59]). This is consistent with the additional finding that preferential targets of the MSL binding might be housekeeping/essential genes that are generally expressed throughout fly development (Gilfillan et al. [@CR37]).

Another intriguing question was whether MSL complex binding coincides with RNA polymerase II (RNA-PolII) activity on X-linked genes. Recent observations suggest a weak or no significant correlation between transcription and MSL complex binding, at least, in salivary glands (Kotlikova et al. [@CR56]; Legube et al. [@CR59]). However, correlation of MSL binding with the active state of gene expression in embryos and different *Drosophila* cell types was indeed observed (Alekseyenko et al. [@CR5]; Gilfillan et al. [@CR37]; Legube et al. [@CR59]). It is therefore likely that tissue-specific differences may influence binding of MSL complex on the X chromosome and that may also in turn be influenced by the expression status of the X-linked genes (Sass et al. [@CR86]). Clearly, the mode of X-chromosomal recognition by the MSL complex is not simple and probably involves multiple steps. Transcription or degenerate DNA elements or subchromosomal context may all contribute to the X-chromosomal specificity of the MSL complex.

MSLs are not alone---the MSL complex meets other nuclear factors {#Sec4}
================================================================

In 1965, Mukherjee and Beermann analyzed RNA synthesis along the male polytene X chromosome by H^3^ uridine incorporation and observed increased transcription in comparison to female X chromosomes (Mukherjee and Beermann [@CR72], [@CR73]). This was the first direct evidence suggesting a role of transcription in dosage compensation. However, despite continuous efforts to discover the components and mechanism of dosage compensation, the question is yet unresolved as to how the MSL complex might impact on transcription.

Our knowledge about the various single components of the MSL complex does not explain how the specific twofold transcriptional upregulation is achieved. We know that the upregulation is dependent on the MSL complex, but a direct link to the basal machinery that modulates gene expression is missing. One possibility could be that there is no such direct link. The mechanism of dosage compensation could involve novel functions affecting general chromatin configuration in a unique manner. The other possibility is that the MSL complex contains or interacts with additional general factors that would make the link to established regulatory chromatin transcription systems.

Various levels of chromatin organization are potential regulation points for the mechanism of dosage compensation. There are several reported cases that link the MSL complex to other chromatin-regulating activities/factors. Firstly, there is the JIL1 histone kinase that has been reported to interact with the MSL complex and enriches the X chromosome for H3S10 phosphorylation (Jin et al. [@CR49]). This histone mark has been implicated in chromatin condensation during mitosis and transcription activation, but which of these roles relates to its function in dosage compensation is unclear (Johansen and Johansen [@CR50]). A recent study further suggests a direct involvement of JIL-1 in dosage compensation of genes on the X chromosome (Lerach et al. [@CR60]).

The second possible connection between dosage compensation and general modulators of chromatin state is the chromatin remodeling factor ISWI. In *iswi* mutant male larvae, the X chromosome appears puffed, and this phenotype can be suppressed by a mutation in *mle* (Corona et al. [@CR25]). In addition, acetylation at H4K16 by MOF in vitro inhibits binding of ISWI to chromatin templates (Clapier et al. [@CR22]). Accordingly, it has been suggested that there is a balance between ISWI and MSL complex components, which ensures proper chromatin configuration of the X chromosome (Corona et al. [@CR25]). Recent studies suggest a role of the general chromatin factors such as GAGA, Su(var)3--7, and HP-1 in structure maintenance of the X chromosome and in dosage compensation (Greenberg et al. [@CR38]; Spierer et al. [@CR94]).

As discussed above, the MSL complex can be genetically and functionally linked to various general chromatin factors. However, a direct biochemical link of such factors to MSL complex components nor their connection to the mechanism of dosage compensation has not been shown. The recent biochemical purification of the *Drosophila* and human MSL complexes was therefore bringing some new complementary insights (Mendjan et al. [@CR68]; Smith et al. [@CR92]).

The purification of the *Drosophila* MSL complexes via tagged MOF and MSL3 proteins leads to a number of unexpected observations. The first surprise was that the purifications did not contain some of the expected suspects like MLE, JIL-1, or ISWI. Weak interactions and/or unfavorable purification conditions may be the reason for their absence. The second surprise was that none of the classical transcription-associated factors was found associated with MOF or MSL3. Instead, there seems to be a core MSL complex (containing MSL1, MSL2, MSL3, and MOF) that copurifies with nuclear pore components or associated proteins (Mtor, Nup153, Nup160, Nup98, and Nup154), interband binding proteins (Z4, Chromator/Chriz), and exosome components (Rrp6, Dis3) as well as a number of novel interaction partners. It is interesting to note that of the several proteins tested in this study, only the depletion of nuclear pore associated proteins Mtor and Nup153 by RNA interference led to the loss of both classical immunostaining of MSL proteins on the X chromosome and dosage compensation of at least a subset of X-linked genes (Mendjan et al. [@CR68]). To date, these proteins are unique, apart from the MSLs themselves, in showing such a severe reduction of MSL staining on the X chromosome as a result of their depletion.

The mechanism of dosage compensation---many hints but no clear answers {#Sec5}
======================================================================

Despite much progress in our understanding of MSL interactions with each other or the male X chromosome, it remains a major challenge to decipher the mechanism by which the MSL complex affects gene expression. It has become increasingly clear that dosage compensation involves multiple steps that need to be characterized. The first step comprises the specific recruitment of the MSL complex to the X chromosome. To date, no simple DNA element that would make the X chromosome easily distinguishable from autosomes and allow specific binding of MSLs has been found (Alekseyenko et al. [@CR5]; Dahlsveen et al. [@CR26]; Gilfillan et al. [@CR37]; Legube et al. [@CR59]). This, however, does not mean that the DNA component of chromatin has no role in MSL complex recruitment. Advanced bioinformatic analysis of the X chromosome might lead to the discovery of more complex DNA sequence information that gives some specificity to the X chromosome. In addition, the epigenetic state, specific chromatin configuration, transcription, and degenerated DNA elements could in some combination give the signal for MSL binding.

The second step of dosage compensation is the twofold upregulation of gene expression on the male X (Fig. [4](#Fig4){ref-type="fig"}a). Could the histone modification by MOF be the key to the mechanism of dosage compensation? Acetylation of H4K16 by MOF has been shown to cause derepression of transcription either in an in vitro transcription system or when tethered to a reporter gene in yeast; however, the effects were more than twofold in these systems (Akhtar and Becker [@CR2]). There is a possibility that all the other complex components solely help to target and correctly distribute MOF at the X chromosome, while H4K16 acetylation does the actual job. How could this be achieved? The histone code hypothesis predicted correctly, in some cases, that specific effector proteins bind distinct marks (Jenuwein and Allis [@CR48]; Strahl and Allis [@CR95]). However, the receptor (possibly a bromodomain-containing protein) for H4K16Ac has not been found yet. The local distribution of this mark and MSL proteins along gene coding regions implies transcription elongation as a possible regulation point (Alekseyenko et al. [@CR5]; Gilfillan et al. [@CR37]; Legube et al. [@CR59]; Smith et al. [@CR91]). These data are in agreement with the current model of dosage compensation that implies a role of the MSL complex in facilitating transcription elongation (Fig. [4](#Fig4){ref-type="fig"}a) (Henikoff and Meneely [@CR45]; Smith et al. [@CR91]). In general, histone acetylation has been already suggested to enhance transcription, but this has not been specifically demonstrated for the H4K16 mark (Orphanides and Reinberg [@CR78]; Svejstrup [@CR98]). It is important to note however that the H4K16 residue is directly implicated in higher-order chromatin structure based on structural studies (Dorigo et al. [@CR28]; Shogren-Knaak et al. [@CR89]; Shogren-Knaak and Peterson [@CR88]). Thus, the effect of H4K16 modification that ultimately leads to dosage compensation may involve levels of chromatin organization and function, which are still poorly understood. Fig. 4Dosage compensation working models. **a** The current predominant model of dosage compensation proposes transcription elongation as the main regulating point of the MSL complex. How this is achieved on the molecular level and what is the role of H4K16 acetylation is not yet known (represented by a *question mark*). H4K16Ac is represented by *asterisk*, while nucleosomes are represented by *gray circles*. MSL complex and RNA PolII are represented *by purple and orange ovals*, respectively. X-chromosomal transcript is represented by *gray wiggled line*. **b** MSL proteins are enriched on the 3′ end of X-linked genes, and they have been found to be associated with components of the nuclear pore complex (*NPC*) (Alekseyenko et al. [@CR5]; Gilfillan et al. [@CR37]; Mendjan et al. [@CR68]; Smith et al. [@CR91]). Consequently, speculative models for the molecular mechanism of dosage compensation can be envisaged that could stimulate our thinking about how MSLs might affect transcription elongation. *Model 1* proposes that MSL--NPC interactions might create a specialized X-chromosomal compartment or domain. This model is based on observations in yeast, where the orthologue of Mtor (Mlp1) has been shown to bind transcriptionally active genes (Casolari et al. [@CR19]). Furthermore, transcriptional activity of a gene has the potential to be modulated at the nuclear periphery (Cabal et al. [@CR16]; Taddei et al. [@CR99]). In manner similar to yeast, nuclear pore components in *Drosophila* may also facilitate modulation of transcriptional activity. This can be achieved by organizing chromatin into functional domains. The X chromosome may therefore require such organization to create functional territories where the MSL complex can act cooperatively to regulate the expression of many X-linked genes. *Model 2* proposes that MSLs may link the X chromosome with the nuclear exosome and the NPC and therefore facilitate coupling of transcription elongation and posttranscriptional events such as RNA processing or export. Another interesting possibility is that nuclear pore components like Mtor and/or Nup153 might be involved in efficient processing and maturation of roX RNAs and their efficient incorporation into the MSL complex. The question remains whether these effects are really a consequence of physical tethering of chromatin and/or RNA to the pore or whether dynamic behavior of pore components facilitates such interaction and therefore does not need to occur at the pore. *Model 3* therefore suggests a nuclear pore independent function of Mtor and Nup153 in gene regulation. The *models 1--3* are not mutually exclusive, and depending on the circumstance, one or more modules may contribute to fine tune gene activity

The local enrichment of MSLs at the 3′ end of genes supports the transcription elongation model (Fig. [4](#Fig4){ref-type="fig"}a); however, the mere presence of MSL proteins at the 3′ end of genes is not sufficient to explain mechanistically how MSLs might help facilitate efficient elongation. Integration of the recent data concerning copurification of nuclear pore components and exosome components with MSL proteins into the elongation model of dosage compensation may help to conceptualize how this might be achieved (Fig. [4](#Fig4){ref-type="fig"}b).

One model, drawn from analogies to yeast, is that nuclear pore components may influence dosage compensation through chromatin loop organization and spatial positioning (Casolari et al. [@CR19]; Feuerbach et al. [@CR30]). Mtor and Nup153 in *Drosophila* Schneider cells could affect specific gene or chromosomal domain organization that is required for subsequent mechanisms of chromatin regulation (Fig. [4](#Fig4){ref-type="fig"}b, model 1). This model implies that Mtor and Nup153 are indirectly involved in the upregulation of transcription by participating in a higher hierarchical level of chromatin organization and compartmentalization. How important this aspect can be for optimal gene expression was nicely demonstrated in yeast for galactose-inducible genes that require association with the nuclear pore for optimal induction (Cabal et al. [@CR16]; Taddei et al. [@CR99]). It is interesting to note that for HKX1 gene, localization to the nuclear periphery required sequences at the 3′ end of the gene (Taddei et al. [@CR99]). There are some intriguing parallels with enriched binding of MSL complex also at the 3′ end of genes (Alekseyenko et al. [@CR5]; Gilfillan et al. [@CR37]; Smith et al. [@CR91]). However, the significance of this enrichment remains to be explored.

The second model is that Mtor/Nup153 might have a more direct role on gene expression machinery by linking X-chromosomal transcripts and regulatory exosome components (Fig. [4](#Fig4){ref-type="fig"}b, model 2). Most of the data concerning the role of the exosome in RNA surveillance, coupling with transcription elongation, and collaboration with Mlp/Mtor have been obtained in yeast (Sommer and Nehrbass [@CR93]). The exosome components Rrp6 and Dis3 participate at different steps of mRNA maturation, and they collaborate with the Mlps at essential steps of gene expression (Galy et al. [@CR34]). Recent work has linked the exosome (Rrp6 subunit) to the TREX complex that is thought to couple transcription with export (Libri et al. [@CR62]; Zenklusen et al. [@CR101]). Moreover, the exosome is recruited to active genes through interactions with transcription elongating factors (Andrulis et al. [@CR7]). The Rrp6 subunit has been implicated in quality control of mRNP particles already at a very early step during transcription (Casolari et al. [@CR18]; Hilleren et al. [@CR47]; Libri et al. [@CR62]). The factors that ultimately link the exosome and Mlp proteins are not known in yeast, and whether the MSLs might fulfill this function in *Drosophila* is a matter of speculation.

What would be the role of the MSL proteins in this context? At least three MSLs (MOF, MSL3, and MLE) have been shown to bind RNA (Akhtar et al. [@CR4]; Buscaino et al. [@CR14]; Richter et al. [@CR85]). In addition, two of them (MOF and MSL3) copurify Mtor, suggesting that they could have a mediating role between chromatin, transcription, and pre-mRNA processing. There is a possibility that cotranscriptional pre-mRNA processing represents the point of MSL regulation. The MSL complex could specifically facilitate spatial, cotranscriptional coupling between events in gene expression of X-chromosomal genes. The exosome is involved in the processing and quality control of various mRNPs (Hilleren et al. [@CR47]; Zenklusen et al. [@CR101]). Consequently, it might also be required for processing and subsequent assembly of roX RNAs into the MSL complex. roX2 RNA has been shown to undergo variable splicing that contributes to its function in dosage compensation (Park 2005), raising the possibility that other roX RNA processing events might also be critical. It is also interesting to note that a recent study demonstrated the importance of exosome components for Xist RNA processing that is essential for proper X-chromosome inactivation in mammals (Ciaudo et al. [@CR21]). Future studies on roX RNA processing might uncover another interesting parallel between the dosage compensation systems in *Drosophila* and mammals.

Finally, it can be envisaged that nuclear pore complex members may also function outside of their predominant role as members of the nuclear pore and act as independent submodules for regulating gene activity (Fig. [4](#Fig4){ref-type="fig"}b, model 3). Consistent with this hypothesis, a number of nuclear pore components have been shown to display dynamic behavior or exist as soluble pools in the nucleoplasm (Cordes et al. [@CR24]; Griffis et al. [@CR39], [@CR40]; Hase and Cordes [@CR42]; Hase et al. [@CR43]; Rabut et al. [@CR82]; Zimowska et al. [@CR102]). In this scenario, limited soluble pools of these proteins may bind genic or intergenic regions to function as activators or repressors and in this capacity affect X-chromosomal as well as autosomal gene expression. It is important to note that neither of the above scenarios is mutually exclusive, and combined action of different steps may result in the twofold impact on transcription.

In summary, recent studies have made important advances in our knowledge of dosage compensation in *Drosophila*. They highlight the complexity behind the twofold upregulation of transcription and various levels of chromosomal regulation and gene expression control that might participate in it. One thing is clear: the dosage compensation process will continue to fascinate us for quite sometime to come.

We are very grateful to Max Scott, Wolfram Antonin, and Kent Duncan for their critical reading of this manuscript. We thank the members of the lab for their helpful discussions and Maj Britt Hansen for the help with the figures. We also thank the referees for their helpful suggestions. This work was supported by the "Epigenome" NoE under EU-FP6 and DFG "Epigenetics".

[^1]: Communicated by T. Orr-Weaver
